ReviumRx is an innovative biotechnology company focused on revolutionizing treatment standards through advanced lipid-based therapies. Located in Herzliya, Israel, ReviumRx is dedicated to addressing critical unmet medical needs in antimicrobial resistance, solid tumors, and immunization. The company’s product pipeline includes a next-generation liposomal antibiotic designed to combat resistant bacterial infections and a potent liposomal cancer adjuvant, both engineered to deliver enhanced efficacy and safety. By utilizing proprietary technology based on the successful principles of liposomal drug delivery, ReviumRx ensures precise targeting and controlled release of therapeutics, minimizing systemic side effects while maximizing drug potency.

Developed by the esteemed Professor Barenholz, whose contributions have been pivotal in establishing liposomal technology as a cornerstone in cancer therapy, the ReviumRx platform is poised to transform patient outcomes in challenging diseases. Through ongoing research and innovation, the company aims to lead the way in advanced drug delivery systems that improve health, safety, and quality of life for patients around the world.